(Adds details from EMA statement)
April 20 (Reuters) - Europe's drug regulator said on Tuesday
it had found a possible link between Johnson & Johnson's
COVID-19 vaccine and rare blood clotting issues in adults who
had received the shot in the United States.
The European Medicines Agency (EMA) said its safety
committee concluded that a warning about unusual blood clots
with low blood platelets should be added to the vaccine's
labels.
The EMA found that all instances had occurred in adults
under 60 years, mostly women, within three weeks of vaccination,
adding that all available evidence, including eight reports of
cases in the United States, were part of its assessment.
It also said that most clots had occurred in the brain and
abdomen, similar to AstraZeneca's vaccine, and
reiterated that the vaccine's overall benefits outweigh risks.
(Reporting by Pushkala Aripaka in Bengaluru
Editing by David Goodman and Gareth Jones)
Astrazeneca (AZN)
